Person: ÇELİKEL, ÇİĞDEM
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ÇELİKEL
First Name
ÇİĞDEM
Name
6 results
Search Results
Now showing 1 - 6 of 6
Publication Metadata only Gastrointestinal nöroendokrin tümör patolojisi(Türkiye Klinikleri Özel Sayı, 2020-01-01) ÇELİKEL, ÇİĞDEM; ÇELİKEL Ç.Publication Metadata only Gastrointestinal kanal patolojisinde tuzaklar(Kongre Kitabevi, 2022-01-01) ÇELİKEL, ÇİĞDEM; BOZKURT, SÜHEYLA; ÇELİKEL Ç., GÜLLÜOĞLU M., BOZKURT S., DOĞANAVŞARGİL YAKUT B., SAKA B., GÖKSEL S., YAMAN B.Publication Metadata only COVID-19 gastrointestinal kanal ve karaciğer patolojisi(Türkiye Klinikleri Özel Sayı, 2020-01-01) ÇELİKEL, ÇİĞDEM; ÇELİKEL Ç.Publication Metadata only COVID-19 İmmunopatogenezi: güncel bilgiler ve olası hasar mekanizmaları(Türkiye Klinikleri Özel Sayı, 2020-01-01) ÇELİKEL, ÇİĞDEM; ŞAHİN ÖZKAN H., ÇELİKEL Ç.Publication Unknown Hepatocellular adenomas in the Turkish population: reclassification according to updated World Health Organization criteria(WILEY, 2021) ÇELİKEL, ÇİĞDEM; Deniz, Kemal; Umetsu, Sarah E.; Ferrell, Linda; Yilmaz, Funda; Gulluoglu, Mine; Sagol, Ozgul; Dogusoy, Gulen B.; Kirimlioglu, Hale; Turhan, Nesrin; Doran, Figen; Kepil, Nuray; Celikel, Cigdem A.; Nart, Deniz; Ozguven, Banu Y.; Ceyran, Bahar; Karadag, Nese; Kir, Gozde; Erden, Esra; Yilmaz, Guldal; Akyol, GulenAims Hepatocellular adenoma (HCA) is an uncommon liver neoplasm, and studies of HCA subtypes have been primarily limited to France, the USA, and Japan. The aim of this study was to describe the clinicopathological features of HCA subtypes in Turkey. Methods and results The resection specimens of 59 cases diagnosed as 'hepatocellular adenoma' collected from 15 institutions were reviewed to confirm the diagnosis and to classify them according to the current World Health Organization 2019 classification. Immunostaining for glutamine synthetase, liver fatty acid-binding protein, C-reactive protein, beta-catenin and reticulin was performed. Of the 59 cases, 48 (81%) were diagnosed as HCA. We identified 24 (50%) hepatocyte nuclear factor 1 alpha (HNF1 alpha)-inactivated HCAs, five (10%) inflammatory HCAs, 15 (32%) beta-catenin-activated HCAs, three (6%) beta-catenin-activated inflammatory HCAs, and one (2%) unclassified HCA. HCA patients were predominantly female (female/male ratio of 5:1); they had a median age of 34 years and a median tumour diameter of 60 mm. In the beta-catenin-activated HCA group, nine cases (19%) showed cytoarchitectural atypia, and were also referred to as atypical hepatocellular neoplasms. In the beta-catenin-activated HCA group, three cases (6%) showed focal areas supportive of transition to HCA. The original diagnosis of HCA was changed to well-differentiated hepatocellular carcinoma in nine cases and to focal nodular hyperplasia in two cases. Conclusion In our series, the major HCA subtype was HNF1 alpha-inactivated HCA. We found a low incidence of inflammatory-type HCA. Our data also showed that beta-catenin-activated hepatocellular neoplasms, including cases with atypical histology, constituted a relatively high proportion of the cases. These findings are in contrast to those of most other studies of HCA subtypes.Publication Unknown The natural course of gastric intestinal metaplasia in Turkish patients: A single-center observational cohort study(MARMARA UNIV, FAC MEDICINE, 2021) ÇELİKEL, ÇİĞDEM; Demirtas, Coskun Ozer; Koldas, Mesut; Yilmaz, Metehan; Sahin, Muhammed Zahid; Soykuvvet, Muhammed Talha; Celikel, Cigdem Ataizi; Gunduz, FeyzaObjective: Gastric intestinal metaplasia (GIM) is considered as a predisposing lesion for the development of gastric cancer and is recommended to be kept under surveillance in designated intervals. We aimed to assess the natural course of GIM in a large Turkish cohort. Materials and Methods: We retrospectively reviewed findings from pathology reports of gastric biopsies conducted between 2011 to 2018 to reveal patients diagnosed with solitary GIM in their index pathology report. Progression of GIM was pre-defined as; lowgrade dysplasia (LGD), high-grade dysplasia (HGD), or gastric malignancy. Results: The median follow-up period of the study population was 34 (12-128) months. Out of 109 patients with GIM at the entry, 54 (49.6%) patients had stable GIM, whereas 53 (48.6%) cases had no signs of GIM at their final endoscopy. Only two (1.8%) patients progressed to LGD, but no HGD or malignancy was detected in the follow-up. Conclusion: Although, considered as a premalignant lesion and offered surveillance globally, progression of GIM was very low in a large Turkish cohort. Further prospective studies in larger cohorts are required to enlighten the obscure strategies in the surveillance of gastric malignancy.